Home > Insider Trading > Filing (0001209191-19-043755)

Filing Details

Accession Number:: 0001209191-19-043755
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-30 18:23:39
Reporting Period:: 2019-07-26

Accepted Time:: 2019-07-30 18:23:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1737287	Allogene Therapeutics Inc.	ALLO	Biological Products, (No Disgnostic Substances) (2836)	823562771

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1754937	Alison Moore	210 East Grand Avenue South San Francisco CA 94080	Chief Technical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-07-26	13,193	$2.27	78,566	No	4	M	Direct
Common Stock	Disposition	2019-07-26	13,193	$29.18	65,373	No	4	S	Direct
Common Stock	Acquisiton	2019-07-29	23,815	$2.27	89,188	No	4	M	Direct
Common Stock	Disposition	2019-07-29	23,815	$29.39	65,373	No	4	S	Direct
Common Stock	Acquisiton	2019-07-30	11,819	$2.27	77,192	No	4	M	Direct
Common Stock	Disposition	2019-07-30	11,819	$29.85	65,373	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-07-26	13,193	$0.00	13,193	$2.27
Common Stock	Stock Option (Right to Buy)	Disposition	2019-07-29	23,815	$0.00	23,815	$2.27
Common Stock	Stock Option (Right to Buy)	Disposition	2019-07-30	11,819	$0.00	11,819	$2.27

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
802,663	2028-06-25	No	4	M	Direct
778,848	2028-06-25	No	4	M	Direct
767,029	2028-06-25	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $30.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter.